Ann: Update - Notification of buy-back - NEU, page-28

Here is a transcript.
Highlight is what I think was the key bits of what JP said.
Sounds to me like the strategy is to concentrate of getting Ph3 done. In the meantime, if there's a really good offer that will deliver most of the value of 2591, then they'll be open to it.

Takeaway for me is they'll reject any low ball offers.

"what is the long-term strategy for neuren? do we have a vision to become a big farmer?
oh look you don't have to become a big big farmer um you know what what I've said is the huge value opportunity here is phase three for 2591 rightso the question is how much of that do you want to capture. do you want to capture it all or the majority of it or do you want to capture a small slice of it and let someone else take over now, that's what I've talked about in the past and I've said for us with all the experience we've got now and all the cash that we've got that I think capturing most of the value is the best outcome for shareholders. uh I still believe that now that doesn't necessarily mean you're going to become a big farmer. I mean there's another step beyond that which is commercializing the drug that's a much bigger step you know for us going from phase two trials to a small phase three trial is a pretty small step and we're very confident about our ability to execute that but becoming a commercial company that's going to sell a product is a whole different ball game that would be a complete change to the company and probably a shift to the US to do that so that's not currently our strategy but it is an option in the future if you know if shareholders wanted that option that's an option in the future that you can make during ph three in a decision you can make during ph 3 if you want to so so I think for now you know as I said the strategy is to make as much value as we can at a 2591 for shareholders at the same time delivering it to patients and while we're doing that we're going to be completely open the whole time to discussions with other companies about Partnerships of whatever or if they can deliver the sort of value that we're going to get from that phase three uplift."